|drug2136||NO intervention planned due to the observational study design - only a diagnostic testing Wiki||1.00|
|D003924||Diabetes Mellitus, Type 2 NIH||0.29|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the COVID-19 infection
Description: Change in glucose control will be assessed via glucose levels obtained from blood serum samplesMeasure: Changes in Glucose Llevels Time: Baseline, up to 2 weeks
Description: changes in SpO2 will be measured with a Pulseimetry, an indirect, non-invasive methodMeasure: Changes in SpO2 levels Time: Baseline, up to 2 weeks
Description: Changes in IL 6 will be assessed from blood serum samplesMeasure: Changes in Interleukin 6 (IL6) Time: Baseline, up to 2 weeks
Description: Changes in Chest radiography (X-ray)Measure: Changes in chest structures Time: Baseline, up to 2 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports